Zomedica Presents TRUFORMA(R) Research Findings At Major Veterinary Internal Medicine Conference, Says New Research Data Confirms Superiority Of TRUFORMA's Bulk Acoustic Wave Sensor Technology In Diagnosing Feline Hyperthyroidism

6/6/24 6:35:39 AM ET

Pharmaceuticals and Biotechnology

Health Care

Get the next $ZOM alert in real time by email

The firm announced the presentation of research highlighting the improved diagnostic capabilities of the TRUFORMA® Bulk Acoustic Wave (BAW) platform when evaluating cats for thyroid disease compared to widely utilized chemiluminescent immunoassay (CLIA) platforms.

Get the next $ZOM alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ZOM

Date	Price Target	Rating	Analyst
1/6/2023	$6.00	Buy	Dawson James

More analyst ratings

$ZOM
Press Releases

Fastest customizable press release news feed in the world

Zomedica Launches Quantitative Insulin Assay for Equine Plasma on the TRUFORMA(R) Platform
Combined with Zomedica's eACTH assay, equine veterinarians get same day answers for their PPID and EMS patients ANN ARBOR, MI / ACCESSWIRE / November 14, 2024 / Zomedica Corp. (NYSE:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the launch of its third equine-focused assay - Insulin for equine plasma - for the TRUFORMA In-Clinic Biosensor Testing Platform.Veterinarians test equine insulin levels when they suspect Equine Metabolic Syndrome (EMS) or other forms of insulin dysregulation, as frequently occurs with equine Cushing's disease, or Pituitary Pars Intermedia Dy
11/14/24 6:30:00 AM ET
$ZOM
Pharmaceuticals and Biotechnology
Health Care
Noble Capital Markets Initiates Equity Research Coverage on Zomedica
ANN ARBOR, MI / ACCESSWIRE / November 12, 2024 / Zomedica Corp. (NYSE:ZOM), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, is pleased to announce that Noble Capital Markets has initiated company-sponsored equity research coverage on the Company. The full report by Noble Capital Markets Research Analyst Robert LeBoyer, as well as news and advanced market data on Zomedica Corp., is available on Channelchek.About ZomedicaZomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians innovative therapeutic and diagnostic solutions. Our gold standard Pul
11/12/24 6:30:00 AM ET
$ZOM
Pharmaceuticals and Biotechnology
Health Care
Zomedica to Present at the Sidoti Micro Cap Conference November 14, 2024
ANN ARBOR, MI / ACCESSWIRE / November 8, 2024 / Zomedica Corp. (NYSE:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced that Larry Heaton, Chief Executive Officer, will present and host one-on-one meetings with investors at the Sidoti Micro Cap Conference, taking place on November 13-14, 2024.The presentation will begin at 11:30 ET on November 14, 2024 and can be accessed live here: https://sidoti.zoom.us/webinar/register/WN_bYqPwu5jRaODxkG5UNkqNgZomedica will also host virtual one-on-ones with investors on Thursday, November 14, 2024. To register for the presentation or
11/8/24 6:30:00 AM ET
$ZOM
Pharmaceuticals and Biotechnology
Health Care

Zomedica Announces Third Quarter 2024 Financial Results: Revenue Up 10% to $7 Million; 72% Gross Margin, and $78 Million in Liquidity to Support Growth
ANN ARBOR, MI / ACCESSWIRE / November 7, 2024 / Zomedica Corp. (NYSE:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today reported consolidated financial results for the third quarter ended September 30, 2024."We are very pleased with our performance, highlighted by record third quarter revenue and a double-digit increase compared to last year, which demonstrates that the execution of our growth initiatives has continued to pay dividends. As expected, PulseVet® capital sales rebounded during the third quarter bolstered by a full-strength sales team in the U.S. and continued positive
11/7/24 4:25:00 PM ET
$ZOM
Pharmaceuticals and Biotechnology
Health Care
Zomedica to Report Third Quarter 2024 Financial Results and Provide Business Update on November 7th at 4:30 p.m. ET
ANN ARBOR, MI / ACCESSWIRE / October 23, 2024 / Zomedica Corp. (NYSE:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, will host a conference call and audio-only webcast on Thursday, November 7, 2024, at 4:30 p.m. ET to discuss the Company's operational and financial highlights for its thirdquarter ended September 30, 2024. A question-and-answer session will follow management's prepared remarks.Event: Zomedica Corp. Q3 2024 Financial Results Conference CallDate: Thursday, November 7, 2024Time: 4:30 p.m. Eastern TimeLive Call: +1-800-717-1738 (U.S. Toll-Free) or +1-646-307-1865 (Internat
10/23/24 3:00:00 AM ET
$ZOM
Pharmaceuticals and Biotechnology
Health Care
Zomedica Announces Second Quarter 2024 Financial Results: Revenue of $6.1 Million; 71% Gross Margin, and $83.0 Million in Liquidity to Support Growth
Diagnostic revenues up 68% year-over-year ANN ARBOR, MI / ACCESSWIRE / August 14, 2024 / Zomedica Corp. (NYSE:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today reported consolidated financial results for the second quarter ended June 30, 2024."We are pleased with the progress in the quarter, which represents the highest second quarter for the Company to date. We saw significant growth in our diagnostic product revenue, reflecting growing adoption of our TRUFORMA® and VETGuardian® products. We also enjoyed substantial growth in consumable products, reflecting the robust usage of ou
8/14/24 4:05:00 PM ET
$ZOM
Pharmaceuticals and Biotechnology
Health Care

$ZOM
Leadership Updates

Live Leadership Updates

Zomedica Appoints New Chief Financial Officer
ANN ARBOR, MI / ACCESSWIRE / March 17, 2023 / Zomedica Corp. (NYSE:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, announced that it has appointed Peter L. Donato as its Chief Financial Officer, effective March 16, 2023. Mr. Donato brings over 30 years of public and private company experience in a wide range of finance and business functions primarily in the human health sector, having held a number of senior positions from CFO, President and CEO, Executive Vice President, Senior Vice President, Vice President and Controller. Prior to joining Zomedica, Mr. Donato had a successful consulting
3/17/23 6:30:00 AM ET
$ZOM
Pharmaceuticals and Biotechnology
Health Care
Zomedica Appoints Dr. Pamela Nichols, DVM to Board of Directors
ANN ARBOR, MI / ACCESSWIRE / August 23, 2022 / Zomedica Corp. (NYSE:ZOM) ('Zomedica' or the 'Company'), a veterinary health company offering diagnostic and therapeutic products for companion animals, today announced that Pamela Nichols, DVM has been appointed to its Board of Directors and is joining the Audit and Governance committees.Dr. Nichols is the founder of six successful veterinary hospitals and dog boarding/daycare facilities. Her newest hospital is Animal Care Daybreak in South Jordan Utah, which opened in October of 2019. She earned her doctorate in veterinary medicine at Colorado State University in 1996 and her Canine Rehabilitation Practitioner (CCRP) certification in 2004. She
8/23/22 6:30:00 AM ET
$ZOM
Pharmaceuticals and Biotechnology
Health Care
Karen DeHaan-Fullerton Joins Zomedica as General Counsel and Corporate Secretary
ANN ARBOR, MI / ACCESSWIRE / June 2, 2022 / Zomedica Corp. (NYSE:ZOM) ("Zomedica" or "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, announced that it has appointed Karen DeHaan-Fullerton as its General Counsel and Corporate Secretary. She joined the Zomedica team on May 31, 2022.Ms. DeHaan-Fullerton joins the company with more than 20 years of corporate legal experience, including advising and leading companies through transformation and acquisition activities."Karen is a welcome addition to the Zomedica team, bringing a mix of executive leadership experience and business development knowledge," said Larry Heaton, Ch
6/2/22 6:30:00 AM ET
$ZOM
Pharmaceuticals and Biotechnology
Health Care

Zomedica Presents TRUFORMA(R) Research Findings At Major Veterinary Internal Medicine Conference, Says New Research Data Confirms Superiority Of TRUFORMA's Bulk Acoustic Wave Sensor Technology In Diagnosing Feline Hyperthyroidism

Chat with this insight

Recent Analyst Ratings for $ZOM

$ZOM Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed

$ZOM Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

COO Blair Anthony K bought $18,450 worth of shares (150,000 units at $0.12), increasing direct ownership by 60% to 400,000 units (SEC Form 4)

Vice President of Sales Klass Russell Kevin bought $60,290 worth of shares (500,000 units at $0.12), increasing direct ownership by 50% to 1,500,050 units (SEC Form 4)

CEO Heaton Larry C Ii bought $12,200 worth of shares (100,000 units at $0.12), increasing direct ownership by 25% to 500,000 units (SEC Form 4)

$ZOM SEC Filings

Zomedica Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

Zomedica Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 10-Q filed by Zomedica Corp.

$ZOM Press Releases

Fastest customizable press release news feed in the world

Zomedica Launches Quantitative Insulin Assay for Equine Plasma on the TRUFORMA(R) Platform

Noble Capital Markets Initiates Equity Research Coverage on Zomedica

Zomedica to Present at the Sidoti Micro Cap Conference November 14, 2024

$ZOM Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Dawson James initiated coverage on Zomedica Pharmaceuticals with a new price target

$ZOM Financials

Live finance-specific insights

$ZOM Market Insights

Live Market Insights

$ZOM Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Zomedica Announces Third Quarter 2024 Financial Results: Revenue Up 10% to $7 Million; 72% Gross Margin, and $78 Million in Liquidity to Support Growth

Zomedica to Report Third Quarter 2024 Financial Results and Provide Business Update on November 7th at 4:30 p.m. ET

Zomedica Announces Second Quarter 2024 Financial Results: Revenue of $6.1 Million; 71% Gross Margin, and $83.0 Million in Liquidity to Support Growth

Zomedica Launches New Cortisol Assay for Equine Health on TRUFORMA Platform

Zomedica Secures CE Mark For Its Proprietary Point-Of-Care TRUFORMA Bulk Acoustic Wave Diagnostic Platform

$1.8M Bet On This Health Care Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying

SEC Form 4 filed by Director Powers Johnny D

SEC Form 4 filed by Director Whelan Sean

SEC Form 4 filed by Director Rowe Jeffrey M

$ZOM Leadership Updates

Live Leadership Updates

Zomedica Appoints New Chief Financial Officer

Zomedica Appoints Dr. Pamela Nichols, DVM to Board of Directors

Karen DeHaan-Fullerton Joins Zomedica as General Counsel and Corporate Secretary

Recent Analyst Ratings for
$ZOM

$ZOM
Large Ownership Changes

$ZOM
Insider Purchases

$ZOM
SEC Filings

$ZOM
Press Releases

$ZOM
Analyst Ratings

$ZOM
Financials

$ZOM
Market Insights

$ZOM
Insider Trading

$ZOM
Leadership Updates